Roman Gulati

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi The impact of PLCO control arm contamination on perceived PSA screening efficacy
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Cancer Causes Control 23:827-35. 2012
  2. ncbi What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 20:740-50. 2011
  3. ncbi Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
    Roman Gulati
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biostatistics 11:707-19. 2010
  4. ncbi The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Cancer 118:5955-63. 2012
  5. ncbi Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer
    Evan Y Yu
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 30:1864-70. 2012
  6. ncbi Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2 B230, PO Box 19024, Seattle, WA 98109 1024, USA
    Ann Intern Med 158:145-53. 2013
  7. ncbi Quantifying the role of PSA screening in the US prostate cancer mortality decline
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Causes Control 19:175-81. 2008
  8. ncbi Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach
    Ruth Etzioni
    Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Med Decis Making 28:323-31. 2008
  9. ncbi Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation
    Evan Y Yu
    Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
    J Clin Oncol 28:2668-73. 2010
  10. ncbi Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Epidemiol 64:1412-7. 2011

Detail Information

Publications21

  1. ncbi The impact of PLCO control arm contamination on perceived PSA screening efficacy
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Cancer Causes Control 23:827-35. 2012
    ..To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial...
  2. ncbi What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 20:740-50. 2011
    ....
  3. ncbi Calibrating disease progression models using population data: a critical precursor to policy development in cancer control
    Roman Gulati
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biostatistics 11:707-19. 2010
    ..The model produces representative outcomes for selected PSA screening policies and is shown to be useful for informing the development of sound cancer control policy...
  4. ncbi The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Cancer 118:5955-63. 2012
    ..Prostate cancer mortality rates in the United States declined by >40% between 1991 and 2005. The impact of changes in primary treatment and adjuvant and neoadjuvant hormone therapy on this decline is unknown...
  5. ncbi Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer
    Evan Y Yu
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 30:1864-70. 2012
    ..To investigate changes in bone mineral density (BMD) and fracture risk in men who received intermittent androgen deprivation (IAD) for nonmetastatic, hormone-sensitive prostate cancer...
  6. ncbi Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2 B230, PO Box 19024, Seattle, WA 98109 1024, USA
    Ann Intern Med 158:145-53. 2013
    ..The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh the benefits...
  7. ncbi Quantifying the role of PSA screening in the US prostate cancer mortality decline
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Causes Control 19:175-81. 2008
    ..To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s...
  8. ncbi Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach
    Ruth Etzioni
    Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Med Decis Making 28:323-31. 2008
    ..The objective was to quantify this link between PSA screening and the decline in distant stage incidence...
  9. ncbi Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation
    Evan Y Yu
    Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
    J Clin Oncol 28:2668-73. 2010
    ....
  10. ncbi Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates
    Roman Gulati
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Epidemiol 64:1412-7. 2011
    ..To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States...
  11. ncbi Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial
    Jing Xia
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2 B230, PO Box 19024, Seattle, WA 98109 1024
    J Natl Cancer Inst 105:546-50. 2013
    ....
  12. ncbi The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 70:412-24. 2010
    ..Tumor cells replace bone marrow and can elicit an osteoblastic, osteolytic, or mixed bone response. Our objective was to elucidate the mechanisms and key factors involved in promoting osteoclastogenesis in PCa bone metastasis...
  13. ncbi Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States
    Megan Dann Fesinmeyer
    Fred Hutchinson Cancer Research Center, Department of Veterans Affairs Puget Sound Health Care System, Fairview Avenue North, M2 B230, PO Box 19024, Seattle WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 18:808-15. 2009
    ..0% (under different survival for obese and nonobese cases) in 2002. We conclude that increasing obesity prevalence since 1980 has partially obscured declines in prostate cancer mortality...
  14. ncbi Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends
    Donatello Telesca
    Department of Statistics, University of Washington, Seattle, WA 98195 4322, USA
    Biometrics 64:10-9. 2008
    ....
  15. ncbi Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma
    Dan Lewinshtein
    Virginia Mason Medical Center Urology and Renal Transplantation, Fred Hutchinson Cancer Research Center Human Biology, Seattle, WA, USA
    BJU Int 109:706-12. 2012
    ..To quantify the risk of specific second primary malignancies (SPMs) associated with radiation exposure in these patients...
  16. ncbi Single cell transcriptomic analysis of prostate cancer cells
    Christopher J Welty
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Mol Biol 14:6. 2013
    ..A high stringency threshold, a mean Alexa Fluor® 3 signal intensity above 300, was used for gene detection. Relative expression levels were validated for select genes using real-time PCR (RT-qPCR)...
  17. ncbi Prostate cancer mortality following active surveillance versus immediate radical prostatectomy
    Jing Xia
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, WA, USA
    Clin Cancer Res 18:5471-8. 2012
    ..The purpose of this study is to project prostate cancer mortality under active surveillance followed by radical prostatectomy versus under immediate radical prostatectomy...
  18. ncbi Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos
    Zeina Makhoul
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Am J Clin Nutr 91:777-85. 2010
    ..Few studies have examined the associations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with biomarkers of chronic disease risk in populations with high intakes...
  19. ncbi Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Med Care 51:295-300. 2013
    ....
  20. ncbi Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence
    Ruth Etzioni
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Med Care 51:304-6. 2013
    ..Although we acknowledge the centrality of screening trials in the policy process, we maintain that modeling constitutes a powerful tool for screening trial interpretation and screening policy development...
  21. ncbi Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells
    Colm Morrissey
    Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
    Anticancer Drugs 21:423-32. 2010
    ..This study shows the potential use of artemisinin derivatives as therapeutic candidates for PCa and warrants the initiation of preclinical studies...